Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): A report from the Austrian Stem Cell Transplantation Registry (ASCTR)

Annals of Hematology

Volumn 84, Issue 7, 2005, Pages 462-473

  Nachbaur, David ^a   Greinix, Hildegard T ^b   Koller, Elisabeth ^c   Krieger, Otto ^d   Linkesch, Werner ^e   Kasparu, Hedwig ^d   Pober, Michael ^f   Hinterberger, Wolfgang ^g   Hausmaninger, Hubert ^h   Heistinger, Max ⁱ   Ulsperger, Ernst ^j   Karlhuber, Susanne ^k   Schwinger, Wolfgang ^l   Lindner, Beate ^m  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e UNIVERSITY OF GRAZ   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

^g DANUBE HOSPITAL   (Austria)

^h St Johanns Spital   (Austria)

ⁱ GENERAL HOSPITAL KLAGENFURT   (Austria)

^j GENERAL HOSPITAL LINZ   (Austria)

^k ST ANNA CHILDREN S HOSPITAL   (Austria)

^l MEDICAL UNIVERSITY OF GRAZ   (Austria)

^m Austrian Stem Cell Transplantation Registry   (Austria)

more..

Author keywords

Autologous; Hodgkin' disease; Long term results; Non Hodgkin's lymphoma; Transplantation

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ADVANCED CANCER; ALLOTRANSPLANTATION; ARTICLE; AUSTRALIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; REGISTER; REGRESSION ANALYSIS; SCHOOL CHILD; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AUSTRIA; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 20944450470     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-1003-3     Document Type: Article

References (43)

1. André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Nedellec G, Attal M, Ferme C, Gisselbrecht C (1998) Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933-1940
2. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau J, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262
3. Bierman P, Vose J, Anderson J, Bishop M, Kessinger A, Armitage J (1997) High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's Lymphoma. J Clin Oncol 15:445-450
4. Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavourable relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 10:1485-1488
5. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Kessinger A, Armitage JO (1994) Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534
6. Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Ferme C, Gisselbrecht C (1999) Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 24:747-755
7. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM (1998) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: No evidence for long-term remission. J Clin Oncol 16:13-18
8. Freedman A, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossmann R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333
9. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755
10. Glossmann JP, Josting A, Pfistner B, Paulus U, Engert A, German Hodgkin's Lymphoma Study Group (GHSG) (2002) A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol 81:424-429
11. Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: New representation of old estimators. Stat Med 18:695-706 10.1002/ (SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO;2-F
12. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813
13. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 96:1280-1286
14. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
15. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle cell lymphoma. J Clin Oncol 16:3803-3809
16. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiatelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Creszenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C (2002) High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100:1559-1565
17. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, van Besien K, Horowitz MM (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534-545
18. Lazarus HM, Loberiza FR Jr, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM (2001) Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27:387-396
19. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma - results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 104:2667-2674
20. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054
21. Milligan DW, Ruiz De Elvira C, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, Colombat P, Schmitz N (1999) Secondary leukemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. Br J Haematol 106:1020-1026
22. Milpied N, Gaillarde F, Moreau P, Mahé B, Souchet J, Rapp MJ, Bulabois CE, Morineau N, Harousseau JL (1998) High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience. Bone Marrow Transplant 22:645-650
23. Mounier N, Gisselbrecht C (1998) Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 9 [Suppl 1]:15-21
24. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Cioffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545 10.1056/NEJM199512073332305
25. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP (1989) Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086-2092
26. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz de Elvira C, Taghipour G, Schmitz N (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316
27. Rohatiner A, Johnson P, Price C, Arnott SJ, Amess J, Norton A, Dorey E, Adams K, Whelan J, Matthews J, MacCallum P, Oza A, Lister T (1994) Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184
28. Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E, for the GEL/TAMO Spanish Cooperative Group (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens. Bone Marrow Transplant 27:405-412
29. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever Goldstone AH, Diehl V, for the German Hodgkin's Lymphoma Study Group (GHSG), the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071
30. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP Trial. J Clin Oncol 21:3918-3927
31. Stansfeld A, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, van Unnik J, Wright D (1988) Updated Kiel classification of lymphomas. Lancet 1:292-293 10.1016/ S0140-6736(88)90367-4
32. Stewart DA, Guo D, Gluck S, Morris D, Chaudhry A, deMetz C, Klasssen J, Brown CB, Russell JA (2000) Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 26:383-388
33. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW Jr, Blume KG (1996) Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2:76-85
34. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, Jarque I, Cabllero MD, Ferrà C, López A, García-Larana J, Cabrera R, Carrera D, Ruiz-Romero MD, León A, Rifón J, Díaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altés A, López-Guillermo A, de la Serna J, Fernández-Ranada JM, Sierra J, Conde E, for the Grupo Espanol de Linfomas/Transplante Autó logo de Médula Ósea Spanish Cooperative Group (2001) Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 19:1395-1404
35. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH, on behalf of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Bone Marrow Transplant 20:745-752
36. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH (1999) High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17:3101-3109
37. Sweetenham JW (2001) Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials. Bone Marrow Transplant 28:813-820
38. The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135
39. Van Besien K, Loberiza FR, Bajrunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529
40. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C, Guilhot F, Vose JM, van Besien K, Rizzo JD, Weisenburger DD, Isaacson P, Horowitz MM, Goldstone AH, Lazarus HM, Schmitz N (2003) Outcome of autologous transplantation for mantle cell lymphoma: A study of the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120:793-800
41. Vose JM, Bierman PJ, Weisenberger DD, Lynch JC, Bociek Y, Chan WC, Greiner TC, Armitage JO (2000) Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645
42. Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Dony K, Hansen JA, Petersdorf E, Ronley S, Storb R, Sullivan K, Witherspoon R, Weiden P, Buckner CD (1993) High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11:1329-1335
43. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822